Chronic antidepressant treatment impairs the acquisition of fear extinction

Biological Psychiatry

Volumn 73, Issue 11, 2013, Pages 1078-1086

  Burghardt, Nesha S ^a,b   Sigurdsson, Torfi ^g   Gorman, Jack M ^c   McEwen, Bruce S ^d   Ledoux, Joseph E ^e,f  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c Franklin Behavioral Health Consultants   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

^e NEW YORK UNIVERSITY   (United States)

^f NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^g GOETHE UNIVERSITY   (Germany)

Author keywords

Amygdala; citalopram; extinction; fear conditioning; NR2B subunit; SSRI

Indexed keywords

CITALOPRAM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; SEROTONIN UPTAKE INHIBITOR; TIANEPTINE;

ANIMAL EXPERIMENT; ARTICLE; CONDITIONING; CONTROLLED STUDY; DRUG EFFECT; FEAR; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT DURATION;

ACOUSTIC STIMULATION; AMYGDALA; ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; CITALOPRAM; CONDITIONING, CLASSICAL; DRUG ADMINISTRATION SCHEDULE; EXTINCTION, PSYCHOLOGICAL; FEAR; GENE EXPRESSION REGULATION; LEARNING DISORDERS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; THIAZEPINES;

EID: 84877574540     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2012.10.012     Document Type: Article

References (110)

1. D.S. Baldwin, K.I. Ajel, and M. Garner Pharmacological treatment of generalized anxiety disorder Curr Top Behav Neurosci 2 2010 453 467
2. J. Irons Fluvoxamine in the treatment of anxiety disorders Neuropsychiatr Dis Treat 1 2005 289 299
3. J.M. Kent, J.D. Coplan, and J.M. Gorman Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety Biol Psychiatry 44 1998 812 824
4. M.J. Friedman, C.R. Marmar, D.G. Baker, C.R. Sikes, and G.M. Farfel Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting J Clin Psychiatry 68 2007 711 720
5. Institute of Medicine Treatment of PTSD: An Assessment of the Evidence 2007 National Academies Press Washington, DC
6. D.T. Wong, K.W. Perry, and F.P. Bymaster Case history: The discovery of fluoxetine hydrochloride (Prozac) Nat Rev Drug Discov 4 2005 764 774
7. A.F. Schatzberg, E. Dessain, P. O'Neil, D.L. Katz, and J.O. Cole Recent studies on selective serotonergic antidepressants: Trazodone, fluoxetine, and fluvoxamine J Clin Psychopharmacol 7 1987 44S 49S
8. E. Arce, A.N. Simmons, K.L. Lovero, M.B. Stein, and M.P. Paulus Escitalopram effects on insula and amygdala BOLD activation during emotional processing Psychopharmacology (Berl) 196 2008 661 672
9. W.C. Drevets Neuroimaging abnormalities in the amygdala in mood disorders Ann N Y Acad Sci 985 2003 420 444
10. W.C. Drevets, W. Bogers, and M.E. Raichle Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism Eur Neuropsychopharmacol 12 2002 527 544
11. T. Furmark, M. Tillfors, I. Marteinsdottir, H. Fischer, A. Pissiota, and B. Langstrom Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy Arch Gen Psychiatry 59 2002 425 433
12. C. Windischberger, R. Lanzenberger, A. Holik, C. Spindelegger, P. Stein, and U. Moser Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: A randomized cross-over study Neuroimage 49 2010 1161 1170
13. C.J. Harmer, C.E. Mackay, C.B. Reid, P.J. Cowen, and G.M. Goodwin Antidepressant drug treatment modifies the neural processing of nonconscious threat cues Biol Psychiatry 59 2006 816 820
14. N.S. Burghardt, G.M. Sullivan, B.S. McEwen, J.M. Gorman, and J.E. LeDoux The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: A comparison with tianeptine Biol Psychiatry 55 2004 1171 1178
15. J.E. LeDoux Emotion circuits in the brain Annu Rev Neurosci 23 2000 155 184
16. S. Maren Is there savings for Pavlovian fear conditioning after neurotoxic basolateral amygdala lesions in rats? Neurobiol Learn Mem 76 2001 268 283
17. M.E. Bouton Conditioning, remembering, and forgetting J Exp Psychol Anim B 20 1994 219 231
18. R.A. Rescorla Preservation of Pavlovian associations through extinction Q J Exp Psychol B 49 1996 245 258
19. M.E. Bouton Context, ambiguity, and unlearning: Sources of relapse after behavioral extinction Biol Psychiatry 52 2002 976 986
20. S.M. Rodrigues, G.E. Schafe, and J.E. LeDoux Intra-amygdala blockade of the NR2B subunit of the NMDA receptor disrupts the acquisition but not the expression of fear conditioning J Neurosci 21 2001 6889 6896
21. F. Sotres-Bayon, D.E. Bush, and J.E. LeDoux Acquisition of fear extinction requires activation of NR2B-containing NMDA receptors in the lateral amygdala Neuropsychopharmacology 32 2007 1929 1940
22. D.H. Barlow Long-term outcome for patients with panic disorder treated with cognitive-behavioral therapy J Clin Psychiatry 51 suppl A 1990 17 23
23. B.O. Rothbaum, and A.C. Schwartz Exposure therapy for posttraumatic stress disorder Am J Psychother 56 2002 59 75
24. D.L. Walker, K.J. Ressler, K.T. Lu, and M. Davis Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats J Neurosci 22 2002 2343 2351
25. A.J. Guastella, R. Richardson, P.F. Lovibond, R.M. Rapee, J.E. Gaston, and P. Mitchell A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder Biol Psychiatry 63 2008 544 549
26. S.G. Hofmann, A.E. Meuret, J.A. Smits, N.M. Simon, M.H. Pollack, and K. Eisenmenger Augmentation of exposure therapy with D-cycloserine for social anxiety disorder Arch Gen Psychiatry 63 2006 298 304
27. M.G. Kushner, S.W. Kim, C. Donahue, P. Thuras, D. Adson, and M. Kotlyar D-cycloserine augmented exposure therapy for obsessive-compulsive disorder Biol Psychiatry 62 2007 835 838
28. M.W. Otto, D.F. Tolin, N.M. Simon, G.D. Pearlson, S. Basden, and S.A. Meunier Efficacy of D-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder Biol Psychiatry 67 2010 365 370
29. K.J. Ressler, B.O. Rothbaum, L. Tannenbaum, P. Anderson, K. Graap, and E. Zimand Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobic individuals to facilitate extinction of fear Arch Gen Psychiatry 61 2004 1136 1144
30. S. Wilhelm, U. Buhlmann, D.F. Tolin, S.A. Meunier, G.D. Pearlson, and H.E. Reese Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder Am J Psychiatry 165 2008 335 341 quiz 409
31. D. Ougrin Efficacy of exposure versus cognitive therapy in anxiety disorders: Systematic review and meta-analysis BMC Psychiatry 11 2011 200
32. D.H. Barlow, J.M. Gorman, M.K. Shear, and S.W. Woods Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial JAMA 283 2000 2529 2536
33. I.M. Marks, R.P. Swinson, M. Basoglu, K. Kuch, H. Noshirvani, and G. O'Sullivan Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto Br J Psychiatry 162 1993 776 787
34. K.G. Power, R.J. Simpson, V. Swanson, L.A. Wallace, A.T.C. Feistner, and D. Sharp A controlled comparison of cognitive-behavior therapy, diazepam, and placebo, alone and in combination, for the treatment of generalized anxiety disorder J Anxiety Disord 4 1990 267 292
35. FJ van Apeldoorn, WJ van Hout, PP Mersch, M Huisman, BR Slaap, and WW Hale 3rd Is a combined therapy more effective than either CBT or SSRI alone? Results of a multicenter trial on panic disorder with or without agoraphobia Acta Psychiatr Scand 117 2008 260 270
36. E.B. Foa, M.E. Franklin, and J. Moser Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination? Biol Psychiatry 52 2002 987 997
37. M.E. Franklin, J.S. Abramowitz, D.A. Bux, L.A. Zoellner, and N.C. Feeny Cognitive-behavioral therapy with and without medication in the treatment of obsessive-compulsive disorder Prof Psychol-Res Pr 33 2002 162 168
38. A.J. van Balkom, E. de Haan, P. van Oppen, P. Spinhoven, K.A. Hoogduin, and R. van Dyck Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder J Nerv Ment Dis 186 1998 492 499
39. J.D. Joss, R.M. Burton, and C.A. Keller Memory loss in a patient treated with fluoxetine Ann Pharmacother 37 2003 1800 1803
40. M.W. Otto, R.K. McHugh, and K.M. Kantak Combined pharmacotherapy and cognitive-behavioral therapy for anxiety disorders: Medication effects, glucocorticoids, and attenuated treatment outcomes Clin Psychol-Sci Pr 17 2010 91 103
41. G. Kato, and A.F. Weitsch Neurochemical profile of tianeptine, a new antidepressant drug Clin Neuropharmacol 11 suppl 2 1988 S43 S50
42. P. Svenningsson, H. Bateup, H. Qi, K. Takamiya, R.L. Huganir, and M. Spedding Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine Eur J Neurosci 26 2007 3509 3517
43. I. Malagie, A. Deslandes, and A.M. Gardier Effects of acute and chronic tianeptine administration on serotonin outflow in rats: Comparison with paroxetine by using in vivo microdialysis Eur J Pharmacol 403 2000 55 65
44. B.S. McEwen, S. Chattarji, D.M. Diamond, T.M. Jay, L.P. Reagan, and P. Svenningsson The neurobiological properties of tianeptine (Stablon): From monoamine hypothesis to glutamatergic modulation Mol Psychiatry 15 2010 237 249
45. L.R. Reznikov, C.A. Grillo, G.G. Piroli, R.K. Pasumarthi, L.P. Reagan, and J. Fadel Acute stress-mediated increases in extracellular glutamate levels in the rat amygdala: Differential effects of antidepressant treatment Eur J Neurosci 25 2007 3109 3114
46. F.C. Kugelberg, G. Apelqvist, B. Carlsson, J. Ahlner, and F. Bengtsson In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats Br J Pharmacol 132 2001 1683 1690
47. C. Wikell, G. Apelqvist, B. Carlsson, S. Hjorth, P.B. Bergqvist, and F.C. Kugelberg Pharmacokinetic and pharmacodynamic responses to chronic administration of the selective serotonin reuptake inhibitor citalopram in rats Clin Neuropharmacol 22 1999 327 336
48. W. Couet, J. Girault, F. Latrille, C. Salvadori, and J.B. Fourtillan Kinetic profiles of tianeptine and its MC5 metabolite in plasma, blood and brain after single and chronic intraperitoneal administration in the rat Eur J Drug Metab Pharmacokinet 15 1990 69 74
49. L. Bjerkenstedt, L. Flyckt, K.F. Overo, and O. Lingjaerde Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels Eur J Clin Pharmacol 28 1985 553 557
50. A.J. Wagstaff, D. Ormrod, and C.M. Spencer Tianeptine: A review of its use in depressive disorders CNS Drugs 15 2001 231 259
51. N.S. Burghardt, D.E. Bush, B.S. McEwen, and J.E. LeDoux Acute selective serotonin reuptake inhibitors increase conditioned fear expression: Blockade with a 5-HT(2C) receptor antagonist Biol Psychiatry 62 2007 1111 1118
52. G.E. Schafe, N.V. Nadel, G.M. Sullivan, A. Harris, and J.E. LeDoux Memory consolidation for contextual and auditory fear conditioning is dependent on protein synthesis, PKA, and MAP kinase Learn Mem 6 1999 97 110
53. W. McAllister, and D. McAllister Behavioral measurement of conditioned fear F.R. Brush, A.H. Black, Aversive Conditioning and Learning 1971 Academic Press New York 105 179
54. C. Herry, S. Ciocchi, V. Senn, L. Demmou, C. Muller, and A. Luthi Switching on and off fear by distinct neuronal circuits Nature 454 2008 600 606
55. W.A. Falls, M.J. Miserendino, and M. Davis Extinction of fear-potentiated startle: blockade by infusion of an NMDA antagonist into the amygdala J Neurosci 12 1992 854 863
56. H. Lee, and J.J. Kim Amygdalar NMDA receptors are critical for new fear learning in previously fear-conditioned rats J Neurosci 18 1998 8444 8454
57. C.H. Lin, S.H. Yeh, H.Y. Lu, and P.W. Gean The similarities and diversities of signal pathways leading to consolidation of conditioning and consolidation of extinction of fear memory J Neurosci 23 2003 8310 8317
58. S.L. Parkes, and R.F. Westbrook The basolateral amygdala is critical for the acquisition and extinction of associations between a neutral stimulus and a learned danger signal but not between two neutral stimuli J Neurosci 30 2010 12608 12618
59. M. Hollmann, and S. Heinemann Cloned glutamate receptors Annu Rev Neurosci 17 1994 31 108
60. S. Nakanishi Molecular diversity of glutamate receptors and implications for brain function Science 258 1992 597 603
61. H. Monyer, N. Burnashev, D.J. Laurie, B. Sakmann, and P.H. Seeburg Developmental and regional expression in the rat-brain and functional-properties of 4 NMDA receptors Neuron 12 1994 529 540
62. S.G. Cull-Candy, and D.N. Leszkiewicz Role of distinct NMDA receptor subtypes at central synapses Sci STKE re16 2004 2004
63. N. Kojima, T. Sakamoto, S. Endo, and H. Niki Impairment of conditioned freezing to tone, but not to context, in Fyn-transgenic mice: Relationship to NMDA receptor subunit 2B function Eur J Neurosci 21 2005 1359 1369
64. L. Liu, T.P. Wong, M.F. Pozza, K. Lingenhoehl, Y. Wang, and M. Sheng Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity Science 304 2004 1021 1024
65. R.W. Wong, M. Setou, J. Teng, Y. Takei, and N. Hirokawa Overexpression of motor protein KIF17 enhances spatial and working memory in transgenic mice Proc Natl Acad Sci U S A 99 2002 14500 14505
66. Y. Yoshimura, T. Ohmura, and Y. Komatsu Two forms of synaptic plasticity with distinct dependence on age, experience, and NMDA receptor subtype in rat visual cortex J Neurosci 23 2003 6557 6566
67. M.G. Zhao, H. Toyoda, Y.S. Lee, L.J. Wu, S.W. Ko, and X.H. Zhang Roles of NMDA NR2B subtype receptor in prefrontal long-term potentiation and contextual fear memory Neuron 47 2005 859 872
68. A. Barria, and R. Malinow NMDA receptor subunit composition controls synaptic plasticity by regulating binding to CaMKII Neuron 48 2005 289 301
69. O. Deschaux, G. Spennato, J.L. Moreau, and R. Garcia Chronic treatment with fluoxetine prevents the return of extinguished auditory-cued conditioned fear Psychopharmacology (Berl) 215 2011 231 237
70. M.R. Bennett Synapse regression in depression: The role of 5-HT receptors in modulating NMDA receptor function and synaptic plasticity Aust N Z J Psychiatry 44 2010 301 308
71. E.Y. Yuen, Q. Jiang, P. Chen, Z. Gu, J. Feng, and Z. Yan Serotonin 5-HT1A receptors regulate NMDA receptor channels through a microtubule-dependent mechanism J Neurosci 25 2005 5488 5501
72. P.A. Boyer, P. Skolnick, and L.H. Fossom Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study J Mol Neurosci 10 1998 219 233
73. G. Nowak, R. Trullas, R.T. Layer, P. Skolnick, and I.A. Paul Adaptive-changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid J Pharmacol Exp Ther 265 1993 1380 1386
74. I.A. Paul, G. Nowak, R.T. Layer, P. Popik, and P. Skolnick Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments J Pharmacol Exp Ther 269 1994 95 102
75. R.M. Berman, A. Cappiello, A. Anand, D.A. Oren, G.R. Heninger, and D.S. Charney Antidepressant effects of ketamine in depressed patients Biol Psychiatry 47 2000 351 354
76. C.A. Zarate Jr, J.L. Payne, J. Quiroz, J. Sporn, K.K. Denicoff, and D. Luckenbaugh An open-label trial of riluzole in patients with treatment-resistant major depression Am J Psychiatry 161 2004 171 174
77. C.A. Zarate Jr, J.B. Singh, P.J. Carlson, N.E. Brutsche, R. Ameli, and D.A. Luckenbaugh A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression Arch Gen Psychiatry 63 2006 856 864
78. E. Engin, D. Treit, and C.T. Dickson Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models Neuroscience 161 2009 359 369
79. N. Li, R.J. Liu, J.M. Dwyer, M. Banasr, B. Lee, and H. Son Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure Biol Psychiatry 69 2011 754 761
80. S.J. Mathew, J.M. Amiel, J.D. Coplan, H.A. Fitterling, H.A. Sackeim, and J.M. Gorman Open-label trial of riluzole in generalized anxiety disorder Am J Psychiatry 162 2005 2379 2381
81. S. Maeng, C.A. Zarate Jr, J. Du, R.J. Schloesser, J. McCammon, and G. Chen Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors Biol Psychiatry 63 2008 349 352
82. S.H. Preskorn, B. Baker, S. Kolluri, F.S. Menniti, M. Krams, and J.W. Landen An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder J Clin Psychopharmacol 28 2008 631 637
83. P. Svenningsson, E.T. Tzavara, J.M. Witkin, A.A. Fienberg, G.G. Nomikos, and P. Greengard Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac) Proc Natl Acad Sci U S A 99 2002 3182 3187
84. C. Riaza Bermudo-Soriano, M.M. Perez-Rodriguez, C. Vaquero-Lorenzo, and E. Baca-Garcia New perspectives in glutamate and anxiety Pharmacol Biochem Behav 100 2012 752 774
85. G. Sanacora, G. Treccani, and M. Popoli Towards a glutamate hypothesis of depression: An emerging frontier of neuropsychopharmacology for mood disorders Neuropharmacology 62 2012 63 77
86. P. Skolnick, R.T. Layer, P. Popik, G. Nowak, I.A. Paul, and R. Trullas Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: Implications for the pharmacotherapy of depression Pharmacopsychiatry 29 1996 23 26
87. A. Werner-Seidler, and R. Richardson Effects of D-cycloserine on extinction: Consequences of prior exposure to imipramine Biol Psychiatry 62 2007 1195 1197
88. N.N. Karpova, A. Pickenhagen, J. Lindholm, E. Tiraboschi, N. Kulesskaya, and A. Agustsdottir Fear erasure in mice requires synergy between antidepressant drugs and extinction training Science 334 2011 1731 1734
89. J.J. Kim, R.A. Rison, and M.S. Fanselow Effects of amygdala, hippocampus, and periaqueductal gray lesions on short- and long-term contextual fear Behav Neurosci 107 1993 1093 1098
90. J.E. LeDoux, P. Cicchetti, A. Xagoraris, and L.M. Romanski The lateral amygdaloid nucleus: Sensory interface of the amygdala in fear conditioning J Neurosci 10 1990 1062 1069
91. S. Maren Neurotoxic basolateral amygdala lesions impair learning and memory but not the performance of conditional fear in rats J Neurosci 19 1999 8696 8703
92. M.J. Miserendino, C.B. Sananes, K.R. Melia, and M. Davis Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala Nature 345 1990 716 718
93. R.G. Phillips, and J.E. LeDoux Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning Behav Neurosci 106 1992 274 285
94. F. Borsini, and A. Meli Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology (Berl) 94 1988 147 160
95. G.M. Goodwin, and A.R. Green A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors Br J Pharmacol 84 1985 743 753
96. G. Battaglia, S.Y. Yeh, and E.B. De Souza MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons Pharmacol Biochem Behav 29 1988 269 274
97. R.J. Rodgers, J. Haller, A. Holmes, J. Halasz, T.J. Walton, and P.F. Brain Corticosterone response to the plus-maze: High correlation with risk assessment in rats and mice Physiol Behav 68 1999 47 53
98. W.D. Hirst, B. Abrahamsen, F.E. Blaney, A.R. Calver, L. Aloj, and G.W. Price Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling Mol Pharmacol 64 2003 1295 1308
99. C.R. Pryce Postnatal ontogeny of expression of the corticosteroid receptor genes in mammalian brains: Inter-species and intra-species differences Brain Res Rev 57 2008 596 605
100. Z. Sheng, J. Kawano, A. Yanai, R. Fujinaga, M. Tanaka, and Y. Watanabe Expression of estrogen receptors (alpha, beta) and androgen receptor in serotonin neurons of the rat and mouse dorsal raphe nuclei; sex and species differences Neurosci Res 49 2004 185 196
101. D.C. Blanchard, G. Griebel, and R.J. Blanchard Mouse defensive behaviors: Pharmacological and behavioral assays for anxiety and panic Neurosci Biobehav Rev 25 2001 205 218
102. J.P. Balcombe, N.D. Barnard, and C. Sandusky Laboratory routines cause animal stress Contemp Top Lab Anim Sci 43 2004 42 51
103. N. Andrews, and S.E. File Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety Eur J Pharmacol 235 1993 109 112
104. B.A. Nic Dhonnchadha, J.J. Szalay, C. Achat-Mendes, D.M. Platt, M.W. Otto, and R.D. Spealman D-cycloserine deters reacquisition of cocaine self-administration by augmenting extinction learning Neuropsychopharmacology 35 2010 357 367
105. S.L. Gourley, A.T. Kedves, P. Olausson, and J.R. Taylor A history of corticosterone exposure regulates fear extinction and cortical NR2B, GluR2/3, and BDNF Neuropsychopharmacology 34 2009 707 716
106. J.R. Davidson, E.B. Foa, J.D. Huppert, F.J. Keefe, M.E. Franklin, and J.S. Compton Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia Arch Gen Psychiatry 61 2004 1005 1013
107. E.B. Foa, M.R. Liebowitz, M.J. Kozak, S. Davies, R. Campeas, and M.E. Franklin Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder Am J Psychiatry 162 2005 151 161
108. T.T. Haug, S. Blomhoff, K. Hellstrom, I. Holme, M. Humble, and H.P. Madsbu Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial Br J Psychiatry 182 2003 312 318
109. M.E. Bouton, and R.C. Bolles Contextual control of the extinction of conditioned fear Learn Motiv 10 1979 445 466
110. M.E. Bouton, F.A. Kenney, and C. Rosengard State-dependent fear extinction with two benzodiazepine tranquilizers Behav Neurosci 104 1990 44 55